Asciminib + Nilotinib

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Conditions

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Trial Timeline

Nov 21, 2022 → Jul 7, 2031

NCT ID

NCT05456191

About Asciminib + Nilotinib

Asciminib + Nilotinib is a phase 3 stage product being developed by Novartis for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT05456191. Target conditions include Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.

What happened to similar drugs?

2 of 7 similar drugs in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia were approved

Approved (2) Terminated (1) Active (4)

❌NilotinibNovartisPhase 3

🔄NilotinibNovartisPhase 3

✅NilotinibNovartisApproved

🔄Imatinib + Nilotinib + Bosutinib + Dasatinib + AsciminibNovartisPhase 3

✅AsciminibNovartisApproved

🔄Blinatumomab + Blinatumomab + HyperCVADAmgenPhase 3

🔄Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05456191	Phase 3	Active	Nov 21, 2022	Jul 7, 2031	Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Competing Products

20 competing products in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

See all competitors

Product	Company	Stage	Hype Score
Imatinib Mesylate	Novartis	Phase 2	35
Nilotinib	Novartis	Phase 3	32
Nilotinib	Novartis	Phase 3	40
STI571 400 mg + STI571 600 mg	Novartis	Phase 2	35
Induction Phase + Re-Induction Phase + Post-Remission + Maintenance	Novartis	Phase 2	42
nilotinib	Novartis	Phase 2	35
imatinib mesylate	Novartis	Phase 2	35
Blinatumomab + Asciminib	Novartis	Phase 1/2	39
Asciminib	Novartis	Phase 1	36
Asciminib Pediatric formulation group + Asciminib Adult formulation group	Novartis	Phase 1/2	39
Nilotinib + LDE225	Novartis	Phase 1	29
Nilotinib	Novartis	Approved	43
Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib	Novartis	Phase 3	44
Asciminib	Novartis	Approved	47
Blinatumomab	Amgen	Phase 2	35
Treatment with blinatumomab given subcutaneously.	Amgen	Phase 2	42
Blinatumomab + Blinatumomab + HyperCVAD	Amgen	Phase 3	47
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	47
Bosutinib	Pfizer	Phase 1/2	36
Bosutinib + Bosutinib	Pfizer	Phase 1	29